Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Capital Expenditures for 18 consecutive years, with $104.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 8.33% year-over-year to $104.0 million; the trailing twelve-month figure through Jun 2026 stood at $550.0 million (up 10.0% YoY), and the FY2025 full-year result was $501.0 million, up 0.6% from the prior year.
• Capital Expenditures fell to $104.0 million in Q2 2026 per TEVA's latest filing, from $168.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $168.0 million in Q1 2026 and bottomed at $96.0 million in Q2 2025.
• Historically, Capital Expenditures has averaged $130.3 million across 5 years, with a median of $128.0 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Capital Expenditures retreated 18.49% in 2024, then jumped 32.28% in 2026.
• Over 5 years, Capital Expenditures stood at $142.0 million in 2022, then decreased by 16.2% to $119.0 million in 2023, then rose by 8.4% to $129.0 million in 2024, then increased by 10.08% to $142.0 million in 2025, then retreated by 26.76% to $104.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $104.0 million, $168.0 million, and $142.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.